Pagibaximab | Interleukin Related interleukin-related.com

Product Name :
Pagibaximab

Search keywords :
Lipoteichoic acid

drugId :
null

Target Vo:
Lipoteichoic acid

Target Vo Short Name :
Lipoteichoic acid

Moa_Name:
Lipoteichoic acid inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Applied Molecular Evolution Inc

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Sepsis

Termination Status :
Phase 3 Clinical

China Termination Status :

Highest Status:
Pending

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
TRAF6 Antibody
CLDN1 Antibody
Phospho-ULK1 (Ser556) Antibody: Phospho-ULK1 (Ser556) Antibody is an unconjugated, approximately 113 kDa (Calculated)/130 kDa (Observed), rabbit-derived, anti-ULK1 (Ser556) monoclonal antibody. Phospho-ULK1 (Ser556) Antibody can be used for: WB expriments in human, mouse background without labeling.

Author: Interleukin Related

Related Posts